Ownership and insider activity for Baxter International Inc. (BAX): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution.
Price
| Price | $24.22 |
| Market Cap | $12.5B |
| Exchange | NYSE |
| Country | US |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.80B | $3.39B | $1.84B | $3.33B | $3.73B | $2.95B | $1.72B | $3.08B | $1.76B | $1.97B |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | $1.69B | $1.79B | $1.84B | $1.90B | $2.08B | $2.71B | $2.62B | $1.77B | $1.73B | $1.93B |
| Inventory | $1.43B | $1.48B | $1.67B | $1.65B | $1.92B | $2.45B | $2.68B | $1.92B | $2.05B | $2.23B |
| Total Current Assets | $6.57B | $7.26B | $5.96B | $7.50B | $8.41B | $8.87B | $8.01B | $9.60B | $8.85B | $6.87B |
| Property, Plant & Equipment | $4.29B | $4.59B | $4.53B | $5.12B | $5.33B | $5.81B | $5.24B | $3.21B | $3.18B | $3.19B |
| Goodwill | $2.60B | $3.10B | $3.00B | $3.03B | $3.22B | $9.84B | $6.45B | $5.79B | $5.28B | $4.93B |
| Intangible Assets | $1.11B | $1.37B | $1.41B | $1.47B | $1.67B | $7.79B | $6.79B | $5.92B | $5.22B | $4.37B |
| Total Assets | $15.55B | $17.11B | $15.72B | $18.19B | $20.02B | $33.52B | $28.29B | $28.28B | $25.78B | $20.05B |
| Accounts Payable | $791.0M | $920.0M | $998.0M | $892.0M | $1.04B | $1.25B | $1.11B | $881.0M | $968.0M | $999.0M |
| Short-term Debt | $3.0M | $3.0M | $4.0M | $541.0M | $406.0M | $511.0M | $1.40B | $2.67B | $2.75B | $84.0M |
| Total Current Liabilities | $2.74B | $2.82B | $2.81B | $3.23B | $3.33B | $4.24B | $4.75B | $6.50B | $6.51B | $2.97B |
| Long-term Debt | $2.78B | $3.51B | $3.48B | $4.81B | $5.79B | $17.15B | $15.23B | $11.09B | $10.37B | $9.68B |
| Total Liabilities | $7.27B | $8.00B | $7.85B | $10.28B | $11.29B | $24.40B | $22.39B | $19.81B | $18.76B | $13.95B |
| Retained Earnings | $14.20B | $14.48B | $15.07B | $15.72B | $16.33B | $17.07B | $14.05B | $16.11B | $14.93B | $13.71B |
| Total Equity | $8.29B | $9.12B | $7.84B | $7.88B | $8.69B | $9.08B | $5.83B | $8.40B | $6.96B | $6.13B |
| Total Debt | $2.78B | $3.51B | $3.48B | $5.96B | $6.80B | $18.31B | $17.20B | $14.11B | $13.45B | $10.00B |
| Net Debt | -$19.0M | $118.0M | $1.65B | $2.63B | $3.07B | $15.36B | $15.48B | $11.04B | $11.69B | $8.04B |
| Working Capital | $3.83B | $4.44B | $3.15B | $4.27B | $5.08B | $4.64B | $3.27B | $3.10B | $2.34B | $3.90B |
Financial Health
| Debt / Equity | 1.56 |
| Current Ratio | 1.95 |
| Piotroski F-Score | 3 |
| Altman Z-Score | 2.12 |
Profitability
| Return on Equity | -16.60% |
| Return on Invested Capital | -1.61% |
| Return on Assets | -5.37% |
| Gross Margin | 30.08% |
| Operating Margin | -2.39% |
| Net Margin | -9.27% |
Related companies: ATR · AVTR · BIO · DVA · HIMS · MDGL
Explore sector: Healthcare · Medical - Instruments & Supplies
More sections of BAX: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks